Your search returned over 250 studies. The top 250 studies are being displayed. Please use additional keywords or decrease the search distance. Get alerts for new studies
- Randomized Controlled Trial of Long-term Treatment Effectiveness for Meibomian Gland Dysfunction (MGD) and Dry Eye
Conditions: Meibomian Gland Dysfunction - Dry Eye
Location: Lake Villa, Illinois
- Imatinib Mesylate in Treating Patients With Recurrent Brain Tumor
Conditions: Brain and Central Nervous System Tumors
Location: Des Moines, Iowa
- Imatinib Mesylate in Treating Patients With Recurrent Brain Tumor
Conditions: Brain and Central Nervous System Tumors
Location: Des Moines, Iowa
- Imatinib Mesylate in Treating Patients With Recurrent Brain Tumor
Conditions: Brain and Central Nervous System Tumors
Location: Des Moines, Iowa
- Imatinib Mesylate in Treating Patients With Recurrent Brain Tumor
Conditions: Brain and Central Nervous System Tumors
Location: Des Moines, Iowa
- Imatinib Mesylate in Treating Patients With Recurrent Brain Tumor
Conditions: Brain and Central Nervous System Tumors
Location: Des Moines, Iowa
- Imatinib Mesylate in Treating Patients With Recurrent Brain Tumor
Conditions: Brain and Central Nervous System Tumors
Location: Des Moines, Iowa
- Pentostatin, Cyclophosphamide, and Rituximab Followed By Alemtuzumab in Treating Patients With Relapsed or Refractory B-Cell Chronic Lymphocytic Leuke
Conditions: Leukemia
Location: Des Moines, Iowa
- Pentostatin, Cyclophosphamide, and Rituximab Followed By Alemtuzumab in Treating Patients With Relapsed or Refractory B-Cell Chronic Lymphocytic Leuke
Conditions: Leukemia
Location: Des Moines, Iowa
- Pentostatin, Cyclophosphamide, and Rituximab Followed By Alemtuzumab in Treating Patients With Relapsed or Refractory B-Cell Chronic Lymphocytic Leuke
Conditions: Leukemia
Location: Des Moines, Iowa
- Pentostatin, Cyclophosphamide, and Rituximab Followed By Alemtuzumab in Treating Patients With Relapsed or Refractory B-Cell Chronic Lymphocytic Leuke
Conditions: Leukemia
Location: Des Moines, Iowa
- Pentostatin, Cyclophosphamide, and Rituximab Followed By Alemtuzumab in Treating Patients With Relapsed or Refractory B-Cell Chronic Lymphocytic Leuke
Conditions: Leukemia
Location: Des Moines, Iowa
- Pentostatin, Cyclophosphamide, and Rituximab Followed By Alemtuzumab in Treating Patients With Relapsed or Refractory B-Cell Chronic Lymphocytic Leuke
Conditions: Leukemia
Location: Des Moines, Iowa
- Vincristine, Dactinomycin, and Cyclophosphamide With or Without Radiation Therapy in Treating Patients With Newly Diagnosed Low-Risk Rhabdomyosarcoma
Conditions: Sarcoma
Location: Des Moines, Iowa
- Comparison of Radiation Therapy Regimens in Combination With Chemotherapy in Treating Young Patients With Newly Diagnosed Standard-Risk Medulloblastom
Conditions: Brain and Central Nervous System Tumors
Location: Des Moines, Iowa
- Paclitaxel or Polyglutamate Paclitaxel or Observation in Treating Patients With Stage III or Stage IV Ovarian Epithelial or Peritoneal Cancer or Fallo
Conditions: Fallopian Tube Cancer - Ovarian Cancer - Peritoneal Cavity Cancer
Location: Des Moines, Iowa
- Paclitaxel or Polyglutamate Paclitaxel or Observation in Treating Patients With Stage III or Stage IV Ovarian Epithelial or Peritoneal Cancer or Fallo
Conditions: Fallopian Tube Cancer - Ovarian Cancer - Peritoneal Cavity Cancer
Location: Des Moines, Iowa
- Paclitaxel or Polyglutamate Paclitaxel or Observation in Treating Patients With Stage III or Stage IV Ovarian Epithelial or Peritoneal Cancer or Fallo
Conditions: Fallopian Tube Cancer - Ovarian Cancer - Peritoneal Cavity Cancer
Location: Des Moines, Iowa
- Paclitaxel or Polyglutamate Paclitaxel or Observation in Treating Patients With Stage III or Stage IV Ovarian Epithelial or Peritoneal Cancer or Fallo
Conditions: Fallopian Tube Cancer - Ovarian Cancer - Peritoneal Cavity Cancer
Location: Des Moines, Iowa
- Paclitaxel or Polyglutamate Paclitaxel or Observation in Treating Patients With Stage III or Stage IV Ovarian Epithelial or Peritoneal Cancer or Fallo
Conditions: Fallopian Tube Cancer - Ovarian Cancer - Peritoneal Cavity Cancer
Location: Des Moines, Iowa
- Paclitaxel or Polyglutamate Paclitaxel or Observation in Treating Patients With Stage III or Stage IV Ovarian Epithelial or Peritoneal Cancer or Fallo
Conditions: Fallopian Tube Cancer - Ovarian Cancer - Peritoneal Cavity Cancer
Location: Des Moines, Iowa
- Rituximab and Combination Chemotherapy in Treating Patients With Diffuse Large B-Cell Non-Hodgkin's Lymphoma
Conditions: Lymphoma
Location: Ottumwa, Iowa
- Cetuximab and/or Bevacizumab Combined With Combination Chemotherapy in Treating Patients With Metastatic Colorectal Cancer
Conditions: Colorectal Cancer
Location: Des Moines, Iowa
- Cetuximab and/or Bevacizumab Combined With Combination Chemotherapy in Treating Patients With Metastatic Colorectal Cancer
Conditions: Colorectal Cancer
Location: Des Moines, Iowa
- Cetuximab and/or Bevacizumab Combined With Combination Chemotherapy in Treating Patients With Metastatic Colorectal Cancer
Conditions: Colorectal Cancer
Location: Des Moines, Iowa
- Cetuximab and/or Bevacizumab Combined With Combination Chemotherapy in Treating Patients With Metastatic Colorectal Cancer
Conditions: Colorectal Cancer
Location: Des Moines, Iowa
- Cetuximab and/or Bevacizumab Combined With Combination Chemotherapy in Treating Patients With Metastatic Colorectal Cancer
Conditions: Colorectal Cancer
Location: Des Moines, Iowa
- Cetuximab and/or Bevacizumab Combined With Combination Chemotherapy in Treating Patients With Metastatic Colorectal Cancer
Conditions: Colorectal Cancer
Location: Des Moines, Iowa
- Cetuximab and/or Bevacizumab Combined With Combination Chemotherapy in Treating Patients With Metastatic Colorectal Cancer
Conditions: Colorectal Cancer
Location: Ottumwa, Iowa
- Study to Assess Compliance With Long-Term Mercaptopurine Treatment in Young Patients With Acute Lymphoblastic Leukemia in Remission
Conditions: Leukemia
Location: Des Moines, Iowa
- Azacitidine With or Without Entinostat in Treating Patients With Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, or Acute Myeloid Leukemia
Conditions: Leukemia - Myelodysplastic Syndromes
Location: Ottumwa, Iowa
- Sorafenib and Temsirolimus in Treating Patients With Recurrent Glioblastoma
Conditions: Brain and Central Nervous System Tumors
Location: Des Moines, Iowa
- Sorafenib and Temsirolimus in Treating Patients With Recurrent Glioblastoma
Conditions: Brain and Central Nervous System Tumors
Location: Des Moines, Iowa
- Sorafenib and Temsirolimus in Treating Patients With Recurrent Glioblastoma
Conditions: Brain and Central Nervous System Tumors
Location: Des Moines, Iowa
- Sorafenib and Temsirolimus in Treating Patients With Recurrent Glioblastoma
Conditions: Brain and Central Nervous System Tumors
Location: Des Moines, Iowa
- Sorafenib and Temsirolimus in Treating Patients With Recurrent Glioblastoma
Conditions: Brain and Central Nervous System Tumors
Location: Des Moines, Iowa
- Sorafenib and Temsirolimus in Treating Patients With Recurrent Glioblastoma
Conditions: Brain and Central Nervous System Tumors
Location: Des Moines, Iowa
- Combination Chemotherapy, Radiation Therapy, and/or Surgery in Treating Patients With High-Risk Kidney Tumors
Conditions: Kidney Cancer
Location: Des Moines, Iowa
- Vincristine, Dactinomycin, and Doxorubicin With or Without Radiation Therapy or Observation Only in Treating Younger Patients Who Are Undergoing Surge
Conditions: Kidney Cancer
Location: Des Moines, Iowa
- Combination Chemotherapy and Radiation Therapy in Treating Patients With Newly Diagnosed Rhabdomyosarcoma
Conditions: Sarcoma
Location: Des Moines, Iowa
- Insulin Resistance Intervention After Stroke Trial
Conditions: Stroke - Myocardial Infarction - Diabetes
Location: Des Moines, Iowa
- Insulin Resistance Intervention After Stroke Trial
Conditions: Stroke - Myocardial Infarction - Diabetes
Location: Des Moines, Iowa
- Combination Chemotherapy, PEG-Interferon Alfa-2b, and Surgery in Treating Patients With Osteosarcoma
Conditions: Sarcoma
Location: Des Moines, Iowa
- Glutamic Acid in Reducing Nerve Damage Caused by Vincristine in Young Patients Receiving Vincristine for Wilms' Tumor, Rhabdomyosarcoma, Acute Lymphob
Conditions: Kidney Cancer - Leukemia - Lymphoma - Neurotoxicity - Peripheral Neuropathy - Sarcoma
Location: Des Moines, Iowa
- Combination Chemotherapy With or Without Radiation Therapy in Treating Young Patients With Newly Diagnosed Stage III or Stage IV Wilms Tumor
Conditions: Kidney Cancer - Metastatic Cancer
Location: Des Moines, Iowa
- Combination Chemotherapy and Cetuximab in Treating Patients With Metastatic Esophageal Cancer or Gastroesophageal Junction Cancer
Conditions: Esophageal Cancer
Location: Des Moines, Iowa
- Combination Chemotherapy and Cetuximab in Treating Patients With Metastatic Esophageal Cancer or Gastroesophageal Junction Cancer
Conditions: Esophageal Cancer
Location: Des Moines, Iowa
- Combination Chemotherapy and Cetuximab in Treating Patients With Metastatic Esophageal Cancer or Gastroesophageal Junction Cancer
Conditions: Esophageal Cancer
Location: Des Moines, Iowa
- Combination Chemotherapy and Cetuximab in Treating Patients With Metastatic Esophageal Cancer or Gastroesophageal Junction Cancer
Conditions: Esophageal Cancer
Location: Des Moines, Iowa
- Combination Chemotherapy and Cetuximab in Treating Patients With Metastatic Esophageal Cancer or Gastroesophageal Junction Cancer
Conditions: Esophageal Cancer
Location: Des Moines, Iowa
- Combination Chemotherapy and Cetuximab in Treating Patients With Metastatic Esophageal Cancer or Gastroesophageal Junction Cancer
Conditions: Esophageal Cancer
Location: Des Moines, Iowa
- Combination Chemotherapy and Cetuximab in Treating Patients With Metastatic Esophageal Cancer or Gastroesophageal Junction Cancer
Conditions: Esophageal Cancer
Location: Des Moines, Iowa
- Combination Chemotherapy and Cetuximab in Treating Patients With Metastatic Esophageal Cancer or Gastroesophageal Junction Cancer
Conditions: Esophageal Cancer
Location: Ottumwa, Iowa
- Irinotecan, Oxaliplatin, and Capecitabine as First-Line Therapy in Treating Patients With Metastatic or Unresectable Locally Advanced Small Bowel Canc
Conditions: Small Intestine Cancer
Location: Des Moines, Iowa
- Irinotecan, Oxaliplatin, and Capecitabine as First-Line Therapy in Treating Patients With Metastatic or Unresectable Locally Advanced Small Bowel Canc
Conditions: Small Intestine Cancer
Location: Des Moines, Iowa
- Irinotecan, Oxaliplatin, and Capecitabine as First-Line Therapy in Treating Patients With Metastatic or Unresectable Locally Advanced Small Bowel Canc
Conditions: Small Intestine Cancer
Location: Des Moines, Iowa
- Irinotecan, Oxaliplatin, and Capecitabine as First-Line Therapy in Treating Patients With Metastatic or Unresectable Locally Advanced Small Bowel Canc
Conditions: Small Intestine Cancer
Location: Des Moines, Iowa
- Irinotecan, Oxaliplatin, and Capecitabine as First-Line Therapy in Treating Patients With Metastatic or Unresectable Locally Advanced Small Bowel Canc
Conditions: Small Intestine Cancer
Location: Des Moines, Iowa
- Irinotecan, Oxaliplatin, and Capecitabine as First-Line Therapy in Treating Patients With Metastatic or Unresectable Locally Advanced Small Bowel Canc
Conditions: Small Intestine Cancer
Location: Des Moines, Iowa
- Brain Function in Young Patients Receiving Methotrexate for Acute Lymphoblastic Leukemia
Conditions: Cognitive/Functional Effects - Leukemia - Long-term Effects Secondary to Cancer Therapy in Children - Neurotoxicity - Psychosocial Effects of Cancer and Its Treatment
Location: Des Moines, Iowa
- Everolimus, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma
Conditions: Brain and Central Nervous System Tumors
Location: Des Moines, Iowa
- Everolimus, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma
Conditions: Brain and Central Nervous System Tumors
Location: Des Moines, Iowa
- Everolimus, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma
Conditions: Brain and Central Nervous System Tumors
Location: Des Moines, Iowa
- Everolimus, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma
Conditions: Brain and Central Nervous System Tumors
Location: Des Moines, Iowa
- Everolimus, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma
Conditions: Brain and Central Nervous System Tumors
Location: Des Moines, Iowa
- Everolimus, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma
Conditions: Brain and Central Nervous System Tumors
Location: Des Moines, Iowa
- Carboplatin and Paclitaxel With or Without Bevacizumab After Surgery in Treating Patients With Recurrent Ovarian Epithelial Cancer, Primary Peritoneal
Conditions: Fallopian Tube Cancer - Ovarian Cancer - Malignant Tumor of Peritoneum
Location: Des Moines, Iowa
- Carboplatin and Paclitaxel With or Without Bevacizumab After Surgery in Treating Patients With Recurrent Ovarian Epithelial Cancer, Primary Peritoneal
Conditions: Fallopian Tube Cancer - Ovarian Cancer - Malignant Tumor of Peritoneum
Location: Des Moines, Iowa
- Carboplatin and Paclitaxel With or Without Bevacizumab After Surgery in Treating Patients With Recurrent Ovarian Epithelial Cancer, Primary Peritoneal
Conditions: Fallopian Tube Cancer - Ovarian Cancer - Malignant Tumor of Peritoneum
Location: Des Moines, Iowa
- Carboplatin and Paclitaxel With or Without Bevacizumab After Surgery in Treating Patients With Recurrent Ovarian Epithelial Cancer, Primary Peritoneal
Conditions: Fallopian Tube Cancer - Ovarian Cancer - Malignant Tumor of Peritoneum
Location: Des Moines, Iowa
- Carboplatin and Paclitaxel With or Without Bevacizumab After Surgery in Treating Patients With Recurrent Ovarian Epithelial Cancer, Primary Peritoneal
Conditions: Fallopian Tube Cancer - Ovarian Cancer - Malignant Tumor of Peritoneum
Location: Des Moines, Iowa
- Carboplatin and Paclitaxel With or Without Bevacizumab After Surgery in Treating Patients With Recurrent Ovarian Epithelial Cancer, Primary Peritoneal
Conditions: Fallopian Tube Cancer - Ovarian Cancer - Malignant Tumor of Peritoneum
Location: Des Moines, Iowa
- Tamoxifen or Letrozole With or Without Bevacizumab in Treating Women With Stage III or Stage IV Breast Cancer
Conditions: Breast Cancer
Location: Des Moines, Iowa
- Tamoxifen or Letrozole With or Without Bevacizumab in Treating Women With Stage III or Stage IV Breast Cancer
Conditions: Breast Cancer
Location: Des Moines, Iowa
- Tamoxifen or Letrozole With or Without Bevacizumab in Treating Women With Stage III or Stage IV Breast Cancer
Conditions: Breast Cancer
Location: Des Moines, Iowa
- Tamoxifen or Letrozole With or Without Bevacizumab in Treating Women With Stage III or Stage IV Breast Cancer
Conditions: Breast Cancer
Location: Des Moines, Iowa
- Tamoxifen or Letrozole With or Without Bevacizumab in Treating Women With Stage III or Stage IV Breast Cancer
Conditions: Breast Cancer
Location: Des Moines, Iowa
- Tamoxifen or Letrozole With or Without Bevacizumab in Treating Women With Stage III or Stage IV Breast Cancer
Conditions: Breast Cancer
Location: Des Moines, Iowa
- Tamoxifen or Letrozole With or Without Bevacizumab in Treating Women With Stage III or Stage IV Breast Cancer
Conditions: Breast Cancer
Location: Ottumwa, Iowa
- Fludarabine and Rituximab With or Without Lenalidomide or Cyclophosphamide in Treating Patients With Symptomatic Chronic Lymphocytic Leukemia
Conditions: Leukemia
Location: Des Moines, Iowa
- Fludarabine and Rituximab With or Without Lenalidomide or Cyclophosphamide in Treating Patients With Symptomatic Chronic Lymphocytic Leukemia
Conditions: Leukemia
Location: Des Moines, Iowa
- Fludarabine and Rituximab With or Without Lenalidomide or Cyclophosphamide in Treating Patients With Symptomatic Chronic Lymphocytic Leukemia
Conditions: Leukemia
Location: Des Moines, Iowa
- Fludarabine and Rituximab With or Without Lenalidomide or Cyclophosphamide in Treating Patients With Symptomatic Chronic Lymphocytic Leukemia
Conditions: Leukemia
Location: Des Moines, Iowa
- Fludarabine and Rituximab With or Without Lenalidomide or Cyclophosphamide in Treating Patients With Symptomatic Chronic Lymphocytic Leukemia
Conditions: Leukemia
Location: Des Moines, Iowa
- Fludarabine and Rituximab With or Without Lenalidomide or Cyclophosphamide in Treating Patients With Symptomatic Chronic Lymphocytic Leukemia
Conditions: Leukemia
Location: Des Moines, Iowa
- Fludarabine and Rituximab With or Without Lenalidomide or Cyclophosphamide in Treating Patients With Symptomatic Chronic Lymphocytic Leukemia
Conditions: Leukemia
Location: Ottumwa, Iowa
- Melphalan, Prednisone, and Thalidomide or Lenalidomide in Treating Patients With Newly Diagnosed Multiple Myeloma
Conditions: Multiple Myeloma and Plasma Cell Neoplasm
Location: Des Moines, Iowa
- Melphalan, Prednisone, and Thalidomide or Lenalidomide in Treating Patients With Newly Diagnosed Multiple Myeloma
Conditions: Multiple Myeloma and Plasma Cell Neoplasm
Location: Des Moines, Iowa
- Melphalan, Prednisone, and Thalidomide or Lenalidomide in Treating Patients With Newly Diagnosed Multiple Myeloma
Conditions: Multiple Myeloma and Plasma Cell Neoplasm
Location: Des Moines, Iowa
- Melphalan, Prednisone, and Thalidomide or Lenalidomide in Treating Patients With Newly Diagnosed Multiple Myeloma
Conditions: Multiple Myeloma and Plasma Cell Neoplasm
Location: Des Moines, Iowa
- Melphalan, Prednisone, and Thalidomide or Lenalidomide in Treating Patients With Newly Diagnosed Multiple Myeloma
Conditions: Multiple Myeloma and Plasma Cell Neoplasm
Location: Des Moines, Iowa
- Melphalan, Prednisone, and Thalidomide or Lenalidomide in Treating Patients With Newly Diagnosed Multiple Myeloma
Conditions: Multiple Myeloma and Plasma Cell Neoplasm
Location: Des Moines, Iowa
- Melphalan, Prednisone, and Thalidomide or Lenalidomide in Treating Patients With Newly Diagnosed Multiple Myeloma
Conditions: Multiple Myeloma and Plasma Cell Neoplasm
Location: Ottumwa, Iowa
- Lenalidomide and Dexamethasone With or Without Bortezomib in Treating Patients With Previously Untreated Multiple Myeloma
Conditions: Multiple Myeloma and Plasma Cell Neoplasm
Location: Ottumwa, Iowa
- Capecitabine and Lapatinib With or Without Cixutumumab in Treating Patients With Previously Treated HER2-Positive Stage IIIB, Stage IIIC, or Stage IV
Conditions: Breast Cancer
Location: Des Moines, Iowa
- Capecitabine and Lapatinib With or Without Cixutumumab in Treating Patients With Previously Treated HER2-Positive Stage IIIB, Stage IIIC, or Stage IV
Conditions: Breast Cancer
Location: Des Moines, Iowa
- Capecitabine and Lapatinib With or Without Cixutumumab in Treating Patients With Previously Treated HER2-Positive Stage IIIB, Stage IIIC, or Stage IV
Conditions: Breast Cancer
Location: Des Moines, Iowa
- Capecitabine and Lapatinib With or Without Cixutumumab in Treating Patients With Previously Treated HER2-Positive Stage IIIB, Stage IIIC, or Stage IV
Conditions: Breast Cancer
Location: Des Moines, Iowa
- Capecitabine and Lapatinib With or Without Cixutumumab in Treating Patients With Previously Treated HER2-Positive Stage IIIB, Stage IIIC, or Stage IV
Conditions: Breast Cancer
Location: Des Moines, Iowa
- Capecitabine and Lapatinib With or Without Cixutumumab in Treating Patients With Previously Treated HER2-Positive Stage IIIB, Stage IIIC, or Stage IV
Conditions: Breast Cancer
Location: Des Moines, Iowa
- Capecitabine and Lapatinib With or Without Cixutumumab in Treating Patients With Previously Treated HER2-Positive Stage IIIB, Stage IIIC, or Stage IV
Conditions: Breast Cancer
Location: Ottumwa, Iowa
- Sunitinib as Maintenance Therapy in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer Previously Treated With Combination Chemot
Conditions: Lung Cancer
Location: Des Moines, Iowa
- Sunitinib as Maintenance Therapy in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer Previously Treated With Combination Chemot
Conditions: Lung Cancer
Location: Des Moines, Iowa
- Sunitinib as Maintenance Therapy in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer Previously Treated With Combination Chemot
Conditions: Lung Cancer
Location: Des Moines, Iowa
- Sunitinib as Maintenance Therapy in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer Previously Treated With Combination Chemot
Conditions: Lung Cancer
Location: Des Moines, Iowa
- Sunitinib as Maintenance Therapy in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer Previously Treated With Combination Chemot
Conditions: Lung Cancer
Location: Des Moines, Iowa
- Sunitinib as Maintenance Therapy in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer Previously Treated With Combination Chemot
Conditions: Lung Cancer
Location: Des Moines, Iowa
- Sunitinib as Maintenance Therapy in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer Previously Treated With Combination Chemot
Conditions: Lung Cancer
Location: Ottumwa, Iowa
- Long-Term Follow-Up of Patients Who Have Participated in Children's Oncology Group Studies
Conditions: Brain and Central Nervous System Tumors - Chronic Myeloproliferative Disorders - Leukemia - Long-term Effects Secondary to Cancer Therapy in Children - Lymphoma - Lymphoproliferative Disorder - Multiple Myeloma and Plasma Cell Neoplasm - Myelodysplastic S
Location: Des Moines, Iowa
- A Complicated Skin and Soft-Tissue Infection Patient Registry
Conditions: Abscess - Staphylococcal Skin Infections - Diabetic Foot Infections - Surgical Wound Infection - Cellulitis
Location: Des Moines, Iowa
- Paclitaxel, Paclitaxel Albumin-Stabilized Nanoparticle Formulation, or Ixabepilone With or Without Bevacizumab in Treating Patients With Stage IIIC or
Conditions: Breast Cancer
Location: Des Moines, Iowa
- Paclitaxel, Paclitaxel Albumin-Stabilized Nanoparticle Formulation, or Ixabepilone With or Without Bevacizumab in Treating Patients With Stage IIIC or
Conditions: Breast Cancer
Location: Des Moines, Iowa
- Paclitaxel, Paclitaxel Albumin-Stabilized Nanoparticle Formulation, or Ixabepilone With or Without Bevacizumab in Treating Patients With Stage IIIC or
Conditions: Breast Cancer
Location: Des Moines, Iowa
- Paclitaxel, Paclitaxel Albumin-Stabilized Nanoparticle Formulation, or Ixabepilone With or Without Bevacizumab in Treating Patients With Stage IIIC or
Conditions: Breast Cancer
Location: Des Moines, Iowa
- Paclitaxel, Paclitaxel Albumin-Stabilized Nanoparticle Formulation, or Ixabepilone With or Without Bevacizumab in Treating Patients With Stage IIIC or
Conditions: Breast Cancer
Location: Des Moines, Iowa
- Paclitaxel, Paclitaxel Albumin-Stabilized Nanoparticle Formulation, or Ixabepilone With or Without Bevacizumab in Treating Patients With Stage IIIC or
Conditions: Breast Cancer
Location: Des Moines, Iowa
- Paclitaxel, Paclitaxel Albumin-Stabilized Nanoparticle Formulation, or Ixabepilone With or Without Bevacizumab in Treating Patients With Stage IIIC or
Conditions: Breast Cancer
Location: Ottumwa, Iowa
- Paclitaxel and Cisplatin or Topotecan With or Without Bevacizumab in Treating Patients With Stage IVB, Recurrent, or Persistent Cervical Cancer
Conditions: Cervical Cancer
Location: Des Moines, Iowa
- Paclitaxel and Cisplatin or Topotecan With or Without Bevacizumab in Treating Patients With Stage IVB, Recurrent, or Persistent Cervical Cancer
Conditions: Cervical Cancer
Location: Des Moines, Iowa
- Paclitaxel and Cisplatin or Topotecan With or Without Bevacizumab in Treating Patients With Stage IVB, Recurrent, or Persistent Cervical Cancer
Conditions: Cervical Cancer
Location: Des Moines, Iowa
- Paclitaxel and Cisplatin or Topotecan With or Without Bevacizumab in Treating Patients With Stage IVB, Recurrent, or Persistent Cervical Cancer
Conditions: Cervical Cancer
Location: Des Moines, Iowa
- Paclitaxel and Cisplatin or Topotecan With or Without Bevacizumab in Treating Patients With Stage IVB, Recurrent, or Persistent Cervical Cancer
Conditions: Cervical Cancer
Location: Des Moines, Iowa
- Paclitaxel and Cisplatin or Topotecan With or Without Bevacizumab in Treating Patients With Stage IVB, Recurrent, or Persistent Cervical Cancer
Conditions: Cervical Cancer
Location: Des Moines, Iowa
- Pelvic Radiation Therapy or Vaginal Implant Radiation Therapy, Paclitaxel, and Carboplatin in Treating Patients With High-Risk Stage I or Stage II End
Conditions: Endometrial Cancer - Fatigue - Neurotoxicity
Location: Des Moines, Iowa
- Pelvic Radiation Therapy or Vaginal Implant Radiation Therapy, Paclitaxel, and Carboplatin in Treating Patients With High-Risk Stage I or Stage II End
Conditions: Endometrial Cancer - Fatigue - Neurotoxicity
Location: Des Moines, Iowa
- Pelvic Radiation Therapy or Vaginal Implant Radiation Therapy, Paclitaxel, and Carboplatin in Treating Patients With High-Risk Stage I or Stage II End
Conditions: Endometrial Cancer - Fatigue - Neurotoxicity
Location: Des Moines, Iowa
- Pelvic Radiation Therapy or Vaginal Implant Radiation Therapy, Paclitaxel, and Carboplatin in Treating Patients With High-Risk Stage I or Stage II End
Conditions: Endometrial Cancer - Fatigue - Neurotoxicity
Location: Des Moines, Iowa
- Pelvic Radiation Therapy or Vaginal Implant Radiation Therapy, Paclitaxel, and Carboplatin in Treating Patients With High-Risk Stage I or Stage II End
Conditions: Endometrial Cancer - Fatigue - Neurotoxicity
Location: Des Moines, Iowa
- Pelvic Radiation Therapy or Vaginal Implant Radiation Therapy, Paclitaxel, and Carboplatin in Treating Patients With High-Risk Stage I or Stage II End
Conditions: Endometrial Cancer - Fatigue - Neurotoxicity
Location: Des Moines, Iowa
- Lenalidomide With or Without Epoetin Alfa in Treating Patients With Myelodysplastic Syndrome and Anemia
Conditions: Anemia - Leukemia - Myelodysplastic Syndromes
Location: Des Moines, Iowa
- Lenalidomide With or Without Epoetin Alfa in Treating Patients With Myelodysplastic Syndrome and Anemia
Conditions: Anemia - Leukemia - Myelodysplastic Syndromes
Location: Des Moines, Iowa
- Lenalidomide With or Without Epoetin Alfa in Treating Patients With Myelodysplastic Syndrome and Anemia
Conditions: Anemia - Leukemia - Myelodysplastic Syndromes
Location: Des Moines, Iowa
- Lenalidomide With or Without Epoetin Alfa in Treating Patients With Myelodysplastic Syndrome and Anemia
Conditions: Anemia - Leukemia - Myelodysplastic Syndromes
Location: Des Moines, Iowa
- Lenalidomide With or Without Epoetin Alfa in Treating Patients With Myelodysplastic Syndrome and Anemia
Conditions: Anemia - Leukemia - Myelodysplastic Syndromes
Location: Des Moines, Iowa
- Lenalidomide With or Without Epoetin Alfa in Treating Patients With Myelodysplastic Syndrome and Anemia
Conditions: Anemia - Leukemia - Myelodysplastic Syndromes
Location: Des Moines, Iowa
- Acute Pain Caused by Paclitaxel in Patients With Cancer
Conditions: Chemotherapeutic Agent Toxicity - Neurotoxicity - Pain - Unspecified Adult Solid Tumor, Protocol Specific
Location: Des Moines, Iowa
- Acute Pain Caused by Paclitaxel in Patients With Cancer
Conditions: Chemotherapeutic Agent Toxicity - Neurotoxicity - Pain - Unspecified Adult Solid Tumor, Protocol Specific
Location: Des Moines, Iowa
- Acute Pain Caused by Paclitaxel in Patients With Cancer
Conditions: Chemotherapeutic Agent Toxicity - Neurotoxicity - Pain - Unspecified Adult Solid Tumor, Protocol Specific
Location: Des Moines, Iowa
- Acute Pain Caused by Paclitaxel in Patients With Cancer
Conditions: Chemotherapeutic Agent Toxicity - Neurotoxicity - Pain - Unspecified Adult Solid Tumor, Protocol Specific
Location: Des Moines, Iowa
- Acute Pain Caused by Paclitaxel in Patients With Cancer
Conditions: Chemotherapeutic Agent Toxicity - Neurotoxicity - Pain - Unspecified Adult Solid Tumor, Protocol Specific
Location: Des Moines, Iowa
- Acute Pain Caused by Paclitaxel in Patients With Cancer
Conditions: Chemotherapeutic Agent Toxicity - Neurotoxicity - Pain - Unspecified Adult Solid Tumor, Protocol Specific
Location: Des Moines, Iowa
- Acute Pain Caused by Paclitaxel in Patients With Cancer
Conditions: Chemotherapeutic Agent Toxicity - Neurotoxicity - Pain - Unspecified Adult Solid Tumor, Protocol Specific
Location: Ottumwa, Iowa
- Bevacizumab and Sorafenib as First-Line Therapy in Treating Patients With Locally Advanced or Metastatic Liver Cancer
Conditions: Liver Cancer
Location: Des Moines, Iowa
- Bevacizumab and Sorafenib as First-Line Therapy in Treating Patients With Locally Advanced or Metastatic Liver Cancer
Conditions: Liver Cancer
Location: Des Moines, Iowa
- Bevacizumab and Sorafenib as First-Line Therapy in Treating Patients With Locally Advanced or Metastatic Liver Cancer
Conditions: Liver Cancer
Location: Des Moines, Iowa
- Bevacizumab and Sorafenib as First-Line Therapy in Treating Patients With Locally Advanced or Metastatic Liver Cancer
Conditions: Liver Cancer
Location: Des Moines, Iowa
- Bevacizumab and Sorafenib as First-Line Therapy in Treating Patients With Locally Advanced or Metastatic Liver Cancer
Conditions: Liver Cancer
Location: Des Moines, Iowa
- Bevacizumab and Sorafenib as First-Line Therapy in Treating Patients With Locally Advanced or Metastatic Liver Cancer
Conditions: Liver Cancer
Location: Des Moines, Iowa
- Temozolomide and Radiation Therapy With or Without Bevacizumab in Treating Patients With Newly Diagnosed Glioblastoma
Conditions: Brain and Central Nervous System Tumors
Location: Des Moines, Iowa
- Temozolomide and Radiation Therapy With or Without Bevacizumab in Treating Patients With Newly Diagnosed Glioblastoma
Conditions: Brain and Central Nervous System Tumors
Location: Des Moines, Iowa
- Bevacizumab With or Without Everolimus in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary
Conditions: Fallopian Tube Cancer - Ovarian Cancer - Primary Peritoneal Cavity Cancer
Location: Des Moines, Iowa
- Bevacizumab With or Without Everolimus in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary
Conditions: Fallopian Tube Cancer - Ovarian Cancer - Primary Peritoneal Cavity Cancer
Location: Des Moines, Iowa
- Bevacizumab With or Without Everolimus in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary
Conditions: Fallopian Tube Cancer - Ovarian Cancer - Primary Peritoneal Cavity Cancer
Location: Des Moines, Iowa
- Bevacizumab With or Without Everolimus in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary
Conditions: Fallopian Tube Cancer - Ovarian Cancer - Primary Peritoneal Cavity Cancer
Location: Des Moines, Iowa
- Bevacizumab With or Without Everolimus in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary
Conditions: Fallopian Tube Cancer - Ovarian Cancer - Primary Peritoneal Cavity Cancer
Location: Des Moines, Iowa
- Bevacizumab With or Without Everolimus in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary
Conditions: Fallopian Tube Cancer - Ovarian Cancer - Primary Peritoneal Cavity Cancer
Location: Des Moines, Iowa
- Cisplatin and Etoposide Phosphate With or Without GDC-0449 or Cixutumumab in Treating Patients With Extensive-Stage Small Cell Lung Cancer
Conditions: Lung Cancer
Location: Des Moines, Iowa
- Cisplatin and Etoposide Phosphate With or Without GDC-0449 or Cixutumumab in Treating Patients With Extensive-Stage Small Cell Lung Cancer
Conditions: Lung Cancer
Location: Des Moines, Iowa
- Cisplatin and Etoposide Phosphate With or Without GDC-0449 or Cixutumumab in Treating Patients With Extensive-Stage Small Cell Lung Cancer
Conditions: Lung Cancer
Location: Des Moines, Iowa
- Cisplatin and Etoposide Phosphate With or Without GDC-0449 or Cixutumumab in Treating Patients With Extensive-Stage Small Cell Lung Cancer
Conditions: Lung Cancer
Location: Des Moines, Iowa
- Cisplatin and Etoposide Phosphate With or Without GDC-0449 or Cixutumumab in Treating Patients With Extensive-Stage Small Cell Lung Cancer
Conditions: Lung Cancer
Location: Des Moines, Iowa
- Cisplatin and Etoposide Phosphate With or Without GDC-0449 or Cixutumumab in Treating Patients With Extensive-Stage Small Cell Lung Cancer
Conditions: Lung Cancer
Location: Des Moines, Iowa
- Cisplatin and Etoposide Phosphate With or Without GDC-0449 or Cixutumumab in Treating Patients With Extensive-Stage Small Cell Lung Cancer
Conditions: Lung Cancer
Location: Ottumwa, Iowa
- Collecting Tumor Samples From Patients With Gynecological Tumors
Conditions: Cancer
Location: Des Moines, Iowa
- Collecting Tumor Samples From Patients With Gynecological Tumors
Conditions: Cancer
Location: Des Moines, Iowa
- Collecting Tumor Samples From Patients With Gynecological Tumors
Conditions: Cancer
Location: Des Moines, Iowa
- Collecting Tumor Samples From Patients With Gynecological Tumors
Conditions: Cancer
Location: Des Moines, Iowa
- Collecting Tumor Samples From Patients With Gynecological Tumors
Conditions: Cancer
Location: Des Moines, Iowa
- Collecting Tumor Samples From Patients With Gynecological Tumors
Conditions: Cancer
Location: Des Moines, Iowa
- Study to Assess the Effectiveness of RCHOP With or Without VELCADE in Previously Untreated Non-Germinal Center B-Cell-like Diffuse Large B-Cell Lympho
Conditions: Non-Germinal B-Cell-like (GCB) Diffuse Large B-cell Lymphoma (DLBCL)
Location: Des Moines, Iowa
- Carboplatin, Paclitaxel, and Everolimus in Treating Patients With Previously Untreated Cancer of Unknown Primary
Conditions: Carcinoma of Unknown Primary
Location: Des Moines, Iowa
- Carboplatin, Paclitaxel, and Everolimus in Treating Patients With Previously Untreated Cancer of Unknown Primary
Conditions: Carcinoma of Unknown Primary
Location: Des Moines, Iowa
- Carboplatin, Paclitaxel, and Everolimus in Treating Patients With Previously Untreated Cancer of Unknown Primary
Conditions: Carcinoma of Unknown Primary
Location: Des Moines, Iowa
- Carboplatin, Paclitaxel, and Everolimus in Treating Patients With Previously Untreated Cancer of Unknown Primary
Conditions: Carcinoma of Unknown Primary
Location: Des Moines, Iowa
- Carboplatin, Paclitaxel, and Everolimus in Treating Patients With Previously Untreated Cancer of Unknown Primary
Conditions: Carcinoma of Unknown Primary
Location: Des Moines, Iowa
- Carboplatin, Paclitaxel, and Everolimus in Treating Patients With Previously Untreated Cancer of Unknown Primary
Conditions: Carcinoma of Unknown Primary
Location: Des Moines, Iowa
- Carboplatin, Paclitaxel, and Everolimus in Treating Patients With Previously Untreated Cancer of Unknown Primary
Conditions: Carcinoma of Unknown Primary
Location: Ottumwa, Iowa
- Gemcitabine Hydrochloride and Cisplatin With or Without Bevacizumab in Treating Patients With Advanced Urinary Tract Cancer
Conditions: Bladder Cancer - Prostate Cancer - Transitional Cell Cancer of the Renal Pelvis and Ureter - Urethral Cancer
Location: Des Moines, Iowa
- Gemcitabine Hydrochloride and Cisplatin With or Without Bevacizumab in Treating Patients With Advanced Urinary Tract Cancer
Conditions: Bladder Cancer - Prostate Cancer - Transitional Cell Cancer of the Renal Pelvis and Ureter - Urethral Cancer
Location: Des Moines, Iowa
- Gemcitabine Hydrochloride and Cisplatin With or Without Bevacizumab in Treating Patients With Advanced Urinary Tract Cancer
Conditions: Bladder Cancer - Prostate Cancer - Transitional Cell Cancer of the Renal Pelvis and Ureter - Urethral Cancer
Location: Des Moines, Iowa
- Gemcitabine Hydrochloride and Cisplatin With or Without Bevacizumab in Treating Patients With Advanced Urinary Tract Cancer
Conditions: Bladder Cancer - Prostate Cancer - Transitional Cell Cancer of the Renal Pelvis and Ureter - Urethral Cancer
Location: Des Moines, Iowa
- Gemcitabine Hydrochloride and Cisplatin With or Without Bevacizumab in Treating Patients With Advanced Urinary Tract Cancer
Conditions: Bladder Cancer - Prostate Cancer - Transitional Cell Cancer of the Renal Pelvis and Ureter - Urethral Cancer
Location: Des Moines, Iowa
- Gemcitabine Hydrochloride and Cisplatin With or Without Bevacizumab in Treating Patients With Advanced Urinary Tract Cancer
Conditions: Bladder Cancer - Prostate Cancer - Transitional Cell Cancer of the Renal Pelvis and Ureter - Urethral Cancer
Location: Des Moines, Iowa
- Gemcitabine Hydrochloride and Cisplatin With or Without Bevacizumab in Treating Patients With Advanced Urinary Tract Cancer
Conditions: Bladder Cancer - Prostate Cancer - Transitional Cell Cancer of the Renal Pelvis and Ureter - Urethral Cancer
Location: Ottumwa, Iowa
- Carboplatin and Paclitaxel With or Without Cisplatin and Radiation Therapy in Treating Patients With Stage I, Stage II, Stage III, or Stage IVA Endome
Conditions: Endometrial Cancer
Location: Des Moines, Iowa
- Carboplatin and Paclitaxel With or Without Cisplatin and Radiation Therapy in Treating Patients With Stage I, Stage II, Stage III, or Stage IVA Endome
Conditions: Endometrial Cancer
Location: Des Moines, Iowa
- Carboplatin and Paclitaxel With or Without Cisplatin and Radiation Therapy in Treating Patients With Stage I, Stage II, Stage III, or Stage IVA Endome
Conditions: Endometrial Cancer
Location: Des Moines, Iowa
- Carboplatin and Paclitaxel With or Without Cisplatin and Radiation Therapy in Treating Patients With Stage I, Stage II, Stage III, or Stage IVA Endome
Conditions: Endometrial Cancer
Location: Des Moines, Iowa
- Carboplatin and Paclitaxel With or Without Cisplatin and Radiation Therapy in Treating Patients With Stage I, Stage II, Stage III, or Stage IVA Endome
Conditions: Endometrial Cancer
Location: Des Moines, Iowa
- Carboplatin and Paclitaxel With or Without Cisplatin and Radiation Therapy in Treating Patients With Stage I, Stage II, Stage III, or Stage IVA Endome
Conditions: Endometrial Cancer
Location: Des Moines, Iowa
- Study of Blood Samples From Newborns With Down Syndrome
Conditions: Leukemia
Location: Des Moines, Iowa
- Carboplatin, Paclitaxel, and Bevacizumab With or Without Everolimus in Treating Patients With Metastatic Malignant Melanoma
Conditions: Melanoma (Skin)
Location: Des Moines, Iowa
- Carboplatin, Paclitaxel, and Bevacizumab With or Without Everolimus in Treating Patients With Metastatic Malignant Melanoma
Conditions: Melanoma (Skin)
Location: Des Moines, Iowa
- Carboplatin, Paclitaxel, and Bevacizumab With or Without Everolimus in Treating Patients With Metastatic Malignant Melanoma
Conditions: Melanoma (Skin)
Location: Des Moines, Iowa
- Carboplatin, Paclitaxel, and Bevacizumab With or Without Everolimus in Treating Patients With Metastatic Malignant Melanoma
Conditions: Melanoma (Skin)
Location: Des Moines, Iowa
- Carboplatin, Paclitaxel, and Bevacizumab With or Without Everolimus in Treating Patients With Metastatic Malignant Melanoma
Conditions: Melanoma (Skin)
Location: Des Moines, Iowa
- Carboplatin, Paclitaxel, and Bevacizumab With or Without Everolimus in Treating Patients With Metastatic Malignant Melanoma
Conditions: Melanoma (Skin)
Location: Des Moines, Iowa
- Carboplatin, Paclitaxel, and Bevacizumab With or Without Everolimus in Treating Patients With Metastatic Malignant Melanoma
Conditions: Melanoma (Skin)
Location: Ottumwa, Iowa
- Paclitaxel, Carboplatin, and Bevacizumab or Paclitaxel, Carboplatin, and Temsirolimus or Ixabepilone, Carboplatin, and Bevacizumab in Treating Patient
Conditions: Endometrial Cancer
Location: Des Moines, Iowa
- Paclitaxel, Carboplatin, and Bevacizumab or Paclitaxel, Carboplatin, and Temsirolimus or Ixabepilone, Carboplatin, and Bevacizumab in Treating Patient
Conditions: Endometrial Cancer
Location: Des Moines, Iowa
- Paclitaxel, Carboplatin, and Bevacizumab or Paclitaxel, Carboplatin, and Temsirolimus or Ixabepilone, Carboplatin, and Bevacizumab in Treating Patient
Conditions: Endometrial Cancer
Location: Des Moines, Iowa
- Paclitaxel, Carboplatin, and Bevacizumab or Paclitaxel, Carboplatin, and Temsirolimus or Ixabepilone, Carboplatin, and Bevacizumab in Treating Patient
Conditions: Endometrial Cancer
Location: Des Moines, Iowa
- Paclitaxel, Carboplatin, and Bevacizumab or Paclitaxel, Carboplatin, and Temsirolimus or Ixabepilone, Carboplatin, and Bevacizumab in Treating Patient
Conditions: Endometrial Cancer
Location: Des Moines, Iowa
- Paclitaxel, Carboplatin, and Bevacizumab or Paclitaxel, Carboplatin, and Temsirolimus or Ixabepilone, Carboplatin, and Bevacizumab in Treating Patient
Conditions: Endometrial Cancer
Location: Des Moines, Iowa
- Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Liver Cancer
Conditions: Liver Cancer
Location: Des Moines, Iowa
- Lisinopril or Carvedilol Phosphate in Reducing Side Effects in Women With HER2-Positive Breast Cancer Receiving Trastuzumab
Conditions: Breast Cancer - Cardiac Toxicity
Location: Des Moines, Iowa
- Lisinopril or Carvedilol Phosphate in Reducing Side Effects in Women With HER2-Positive Breast Cancer Receiving Trastuzumab
Conditions: Breast Cancer - Cardiac Toxicity
Location: Des Moines, Iowa
- Lisinopril or Carvedilol Phosphate in Reducing Side Effects in Women With HER2-Positive Breast Cancer Receiving Trastuzumab
Conditions: Breast Cancer - Cardiac Toxicity
Location: Des Moines, Iowa
- Sorafenib Tosylate With or Without Doxorubicin Hydrochloride in Treating Patients With Locally Advanced or Metastatic Liver Cancer
Conditions: Liver Cancer
Location: Ottumwa, Iowa
- Seneca Valley Virus-001 After Chemotherapy in Treating Patients With Extensive-Stage Small Cell Lung Cancer
Conditions: Lung Cancer
Location: Des Moines, Iowa
- Seneca Valley Virus-001 After Chemotherapy in Treating Patients With Extensive-Stage Small Cell Lung Cancer
Conditions: Lung Cancer
Location: Des Moines, Iowa
- Seneca Valley Virus-001 After Chemotherapy in Treating Patients With Extensive-Stage Small Cell Lung Cancer
Conditions: Lung Cancer
Location: Des Moines, Iowa
- Seneca Valley Virus-001 After Chemotherapy in Treating Patients With Extensive-Stage Small Cell Lung Cancer
Conditions: Lung Cancer
Location: Des Moines, Iowa
- Seneca Valley Virus-001 After Chemotherapy in Treating Patients With Extensive-Stage Small Cell Lung Cancer
Conditions: Lung Cancer
Location: Des Moines, Iowa
- Seneca Valley Virus-001 After Chemotherapy in Treating Patients With Extensive-Stage Small Cell Lung Cancer
Conditions: Lung Cancer
Location: Des Moines, Iowa
- AMG 102 in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer
Conditions: Fallopian Tube Cancer - Ovarian Cancer - Malignant Tumor of Peritoneum
Location: Des Moines, Iowa
- AMG 102 in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer
Conditions: Fallopian Tube Cancer - Ovarian Cancer - Malignant Tumor of Peritoneum
Location: Des Moines, Iowa
- AMG 102 in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer
Conditions: Fallopian Tube Cancer - Ovarian Cancer - Malignant Tumor of Peritoneum
Location: Des Moines, Iowa
- AMG 102 in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer
Conditions: Fallopian Tube Cancer - Ovarian Cancer - Malignant Tumor of Peritoneum
Location: Des Moines, Iowa
- AMG 102 in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer
Conditions: Fallopian Tube Cancer - Ovarian Cancer - Malignant Tumor of Peritoneum
Location: Des Moines, Iowa
- AMG 102 in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer
Conditions: Fallopian Tube Cancer - Ovarian Cancer - Malignant Tumor of Peritoneum
Location: Des Moines, Iowa
- Gemcitabine Hydrochloride or Pemetrexed Disodium and Carboplatin With or Without Celecoxib in Treating Patients With Advanced Non-Small Cell Lung Canc
Conditions: Lung Cancer
Location: Des Moines, Iowa
- Bortezomib, Liposomal Doxorubicin Hydrochloride, Dexamethasone, and Cyclophosphamide in Treating Patients With Multiple Myeloma That Relapsed After Au
Conditions: Multiple Myeloma and Plasma Cell Neoplasm
Location: Des Moines, Iowa
- Bortezomib, Liposomal Doxorubicin Hydrochloride, Dexamethasone, and Cyclophosphamide in Treating Patients With Multiple Myeloma That Relapsed After Au
Conditions: Multiple Myeloma and Plasma Cell Neoplasm
Location: Des Moines, Iowa
- Bortezomib, Liposomal Doxorubicin Hydrochloride, Dexamethasone, and Cyclophosphamide in Treating Patients With Multiple Myeloma That Relapsed After Au
Conditions: Multiple Myeloma and Plasma Cell Neoplasm
Location: Des Moines, Iowa
- Bortezomib, Liposomal Doxorubicin Hydrochloride, Dexamethasone, and Cyclophosphamide in Treating Patients With Multiple Myeloma That Relapsed After Au
Conditions: Multiple Myeloma and Plasma Cell Neoplasm
Location: Des Moines, Iowa
- Bortezomib, Liposomal Doxorubicin Hydrochloride, Dexamethasone, and Cyclophosphamide in Treating Patients With Multiple Myeloma That Relapsed After Au
Conditions: Multiple Myeloma and Plasma Cell Neoplasm
Location: Des Moines, Iowa
- Bortezomib, Liposomal Doxorubicin Hydrochloride, Dexamethasone, and Cyclophosphamide in Treating Patients With Multiple Myeloma That Relapsed After Au
Conditions: Multiple Myeloma and Plasma Cell Neoplasm
Location: Des Moines, Iowa
- Changes in Brain Function in Patients With Stage I, Stage II, Stage III, or Stage IV Ovarian, Primary Peritoneal, or Fallopian Tube Cancer Who Are Rec
Conditions: Cognitive/Functional Effects - Fallopian Tube Cancer - Ovarian Cancer - Primary Peritoneal Cavity Cancer
Location: Des Moines, Iowa
- Changes in Brain Function in Patients With Stage I, Stage II, Stage III, or Stage IV Ovarian, Primary Peritoneal, or Fallopian Tube Cancer Who Are Rec
Conditions: Cognitive/Functional Effects - Fallopian Tube Cancer - Ovarian Cancer - Primary Peritoneal Cavity Cancer
Location: Des Moines, Iowa
- Changes in Brain Function in Patients With Stage I, Stage II, Stage III, or Stage IV Ovarian, Primary Peritoneal, or Fallopian Tube Cancer Who Are Rec
Conditions: Cognitive/Functional Effects - Fallopian Tube Cancer - Ovarian Cancer - Primary Peritoneal Cavity Cancer
Location: Des Moines, Iowa
- Changes in Brain Function in Patients With Stage I, Stage II, Stage III, or Stage IV Ovarian, Primary Peritoneal, or Fallopian Tube Cancer Who Are Rec
Conditions: Cognitive/Functional Effects - Fallopian Tube Cancer - Ovarian Cancer - Primary Peritoneal Cavity Cancer
Location: Des Moines, Iowa
- Changes in Brain Function in Patients With Stage I, Stage II, Stage III, or Stage IV Ovarian, Primary Peritoneal, or Fallopian Tube Cancer Who Are Rec
Conditions: Cognitive/Functional Effects - Fallopian Tube Cancer - Ovarian Cancer - Primary Peritoneal Cavity Cancer
Location: Des Moines, Iowa
- Changes in Brain Function in Patients With Stage I, Stage II, Stage III, or Stage IV Ovarian, Primary Peritoneal, or Fallopian Tube Cancer Who Are Rec
Conditions: Cognitive/Functional Effects - Fallopian Tube Cancer - Ovarian Cancer - Primary Peritoneal Cavity Cancer
Location: Des Moines, Iowa
- Carboplatin and Paclitaxel or Oxaliplatin and Capecitabine, With or Without Bevacizumab, as First-Line Therapy in Treating Patients With Newly Diagnos
Conditions: Fallopian Tube Cancer - Ovarian Cancer
Location: Des Moines, Iowa
- Carboplatin and Paclitaxel or Oxaliplatin and Capecitabine, With or Without Bevacizumab, as First-Line Therapy in Treating Patients With Newly Diagnos
Conditions: Fallopian Tube Cancer - Ovarian Cancer
Location: Des Moines, Iowa
- Carboplatin and Paclitaxel or Oxaliplatin and Capecitabine, With or Without Bevacizumab, as First-Line Therapy in Treating Patients With Newly Diagnos
Conditions: Fallopian Tube Cancer - Ovarian Cancer
Location: Des Moines, Iowa
- Carboplatin and Paclitaxel or Oxaliplatin and Capecitabine, With or Without Bevacizumab, as First-Line Therapy in Treating Patients With Newly Diagnos
Conditions: Fallopian Tube Cancer - Ovarian Cancer
Location: Des Moines, Iowa
- Carboplatin and Paclitaxel or Oxaliplatin and Capecitabine, With or Without Bevacizumab, as First-Line Therapy in Treating Patients With Newly Diagnos
Conditions: Fallopian Tube Cancer - Ovarian Cancer
Location: Des Moines, Iowa
- Carboplatin and Paclitaxel or Oxaliplatin and Capecitabine, With or Without Bevacizumab, as First-Line Therapy in Treating Patients With Newly Diagnos
Conditions: Fallopian Tube Cancer - Ovarian Cancer
Location: Des Moines, Iowa
- Paclitaxel, Cisplatin, and Cetuximab Followed By Cetuximab and Intensity-Modulated Radiation Therapy in Treating Patients With HPV-Associated Stage II
Conditions: Head and Neck Cancer - Precancerous Condition
Location: Des Moines, Iowa
- Paclitaxel, Cisplatin, and Cetuximab Followed By Cetuximab and Intensity-Modulated Radiation Therapy in Treating Patients With HPV-Associated Stage II
Conditions: Head and Neck Cancer - Precancerous Condition
Location: Des Moines, Iowa
- Paclitaxel, Cisplatin, and Cetuximab Followed By Cetuximab and Intensity-Modulated Radiation Therapy in Treating Patients With HPV-Associated Stage II
Conditions: Head and Neck Cancer - Precancerous Condition
Location: Des Moines, Iowa
- Paclitaxel, Cisplatin, and Cetuximab Followed By Cetuximab and Intensity-Modulated Radiation Therapy in Treating Patients With HPV-Associated Stage II
Conditions: Head and Neck Cancer - Precancerous Condition
Location: Des Moines, Iowa
- Paclitaxel, Cisplatin, and Cetuximab Followed By Cetuximab and Intensity-Modulated Radiation Therapy in Treating Patients With HPV-Associated Stage II
Conditions: Head and Neck Cancer - Precancerous Condition
Location: Des Moines, Iowa
- Paclitaxel, Cisplatin, and Cetuximab Followed By Cetuximab and Intensity-Modulated Radiation Therapy in Treating Patients With HPV-Associated Stage II
Conditions: Head and Neck Cancer - Precancerous Condition
Location: Des Moines, Iowa
- Left Atrial Pressure Monitoring to Optimize Heart Failure Therapy
Conditions: Advanced Heart Failure
Location: Des Moines, Iowa
- Cediranib Maleate in Treating Patients With Recurrent or Persistent Endometrial Cancer
Conditions: Endometrial Cancer
Location: Des Moines, Iowa
- Cediranib Maleate in Treating Patients With Recurrent or Persistent Endometrial Cancer
Conditions: Endometrial Cancer
Location: Des Moines, Iowa
- Cediranib Maleate in Treating Patients With Recurrent or Persistent Endometrial Cancer
Conditions: Endometrial Cancer
Location: Des Moines, Iowa
|